Amylyx Pharmaceuticals, Inc. AMLX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$41.28M-15.0% | -$33M+12.1% | -$34.39M+52.7% | -$41.44M+43.0% | -$35.91M+69.8% | ||
| $98K-37.2% | $108K-32.5% | $120K-45.7% | $141K-32.2% | $156K-50.5% | ||
| $6.12M-10.4% | $6.39M-5.3% | $7.08M+4.0% | $7.35M-23.2% | $6.83M-31.1% | ||
| $10K-99.5% | $275K— | —— | —— | $1.87M+387% | ||
| -$6.67M+43.8% | -$1.21M+95.4% | —— | —— | -$11.88M-52.8% | ||
| -$1.43M-63.0% | -$2.66M— | —— | -$5.64M-50.1% | -$879K-142% | ||
| -$53K— | $433K+431% | $0— | -$264K+67.2% | $0+100% | ||
| -$327K+45.4% | $0+100% | -$27K+95.3% | -$559K-1.1% | -$599K-10.3% | ||
| -$36.88M+7.4% | -$27.9M+52.7% | -$30.37M+26.9% | -$25.25M+62.1% | -$39.82M-8,044% | ||
| —— | $86K+330% | $24K— | $17K-80.9% | $11K-83.6% | ||
| $19.74M-81.0% | $30.45M— | $58.74M— | $38.99M-75.5% | $103.65M+41.8% | ||
| $36.26M+183% | $29.47M-54.7% | —— | —— | -$43.66M-5,431% | ||
| —— | —— | $191.11M— | —— | $65.58M— | ||
| $3.22M-95.1% | —— | $191.61M+239,407% | —— | $65.66M+50,024% | ||
| -$111K-156% | $118K+122% | $151K-36.0% | $608K+1,659% | $197K+279% | ||
| $2.49M+114% | $1.48M— | $166.63M+6,934% | -$1.68M+98.2% | -$17.62M-5,121% | ||
| $609K-64.2% | $1.06M-41.0% | $1.24M-46.1% | $1.52M-52.1% | $1.7M-34.0% | ||
| $4M— | —— | —— | —— | —— | ||
| $98K-37.2% | $108K-32.5% | $120K-45.7% | $141K-32.2% | $156K-50.5% | ||
| —— | $494K+392% | $494K+392% | $494K+392% | $494K+392% | ||
| -$327K+45.4% | $0+100% | -$27K+95.3% | -$559K-1.1% | -$599K-10.3% | ||
| $300K-41.7% | $295K-41.5% | $336K-31.8% | $584K+20.7% | $515K+8.9% | ||
| $2K+115% | —— | —— | -$11K+15.4% | -$13K+93.6% | ||
| -$1.43M-63.0% | -$2.66M— | —— | -$5.64M-50.1% | -$879K-142% | ||
| -$53K— | $433K+431% | $0— | -$264K+67.2% | $0+100% | ||
| $4M— | —— | —— | —— | —— | ||
| $7.16M+638% | $376K+154% | $2.66M+442% | $72K+53.2% | $970K-32.9% | ||
| $3.94M+345% | $209K+450% | $2.16M+427% | $103K+415% | $885K-32.7% | ||
| -$327K+45.4% | $0+100% | -$27K+95.3% | -$559K-1.1% | -$599K-10.3% | ||
| —— | -$27.99M+52.6% | -$30.39M+26.9% | -$25.27M+62.1% | -$39.84M-7,065% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.